A Phase I Study of TRK-250, a Novel siRNA-Based Oligonucleotide, in Patients with Idiopathic Pulmonary Fibrosis
Journal of Aerosol Medicine and Pulmonary Drug Delivery · 01.12.2023 · 36 (6) · 300-308
DOI: 10.1089/jamp.2023.0014 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Aerosol Medicine and Pulmonary Drug Delivery, erschienen am 01.12.2023. Verfasst von Hiroyuki Doi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Department, Toray Industries, Inc., Tokyo, Japan. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Department, Toray Industries, Inc., Tokyo, Japan.
- Pulmonary Associates, Phoenix, Arizona, USA.
ORCID-Profile: Hiroyuki Doi
Zitieren
APA
Doi, H., Atsumi, J., Baratz, D., & Miyamoto, Y. (2023). A Phase I Study of TRK-250, a Novel siRNA-Based Oligonucleotide, in Patients with Idiopathic Pulmonary Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 36(6), 300-308. https://doi.org/10.1089/jamp.2023.0014
Vancouver
Doi H, Atsumi J, Baratz D, Miyamoto Y. A Phase I Study of TRK-250, a Novel siRNA-Based Oligonucleotide, in Patients with Idiopathic Pulmonary Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2023;36(6):300-308. doi:10.1089/jamp.2023.0014
BibTeX
@article{Doi2023,
author = {Doi, Hiroyuki and Atsumi, Jun and Baratz, David and Miyamoto, Yohei},
title = {A Phase I Study of TRK-250, a Novel siRNA-Based Oligonucleotide, in Patients with Idiopathic Pulmonary Fibrosis},
journal = {Journal of Aerosol Medicine and Pulmonary Drug Delivery},
year = {2023},
volume = {36},
number = {6},
pages = {300--308},
doi = {10.1089/jamp.2023.0014}
}
EUVIMED